Cadence Raises $100M Series C as Clinical AI Moves From Experiment to Infrastructure

Cadence, a New York-based clinical AI company, announced a $100M Series C funding round on June 22, 2026, led by Spark Capital, with participation from Thrive Capital, General Catalyst, Coatue, B Capital, Corewell Health Ventures, Memorial Hermann, and Duke Health. Founded by Chris Altchek (CEO), and Kareem Zaki, Cadence helps health systems manage chronic disease care for older adults between office visits using AI-powered monitoring, clinical workflows, and care teams integrated into provider operations.

The company says it now supports more than 100,000 active patients, partners with more than 20 health systems, tripled annual recurring revenue in 2025, and saves Medicare approximately $2.7M per week. The funding reflects a broader shift in healthcare as AI is increasingly being judged not by demos or investor excitement, but by whether it can reduce costs, improve outcomes, and fit into existing clinical workflows without creating new operational headaches.

What Happened

Healthcare has spent years wrestling with a math problem nobody has solved. The population is aging, chronic disease continues to drive healthcare spending, clinician shortages remain persistent, and demand continues rising while available capacity struggles to keep pace. Most technology companies entering healthcare attack one piece of that equation. Cadence is attempting to address the gap between patient visits, where chronic conditions often worsen unnoticed and where some of the healthcare system's most expensive interventions begin.

That thesis helped Cadence secure a $100M Series C round led by Spark Capital. The investor syndicate includes Thrive Capital, General Catalyst, Coatue, B Capital, Corewell Health Ventures, Memorial Hermann, and Duke Health. The composition of the round matters almost as much as the amount itself because when health systems invest alongside venture firms, the conversation tends to move beyond theoretical disruption and toward clinical adoption, workflow integration, reimbursement models, and patient outcomes. Healthcare has a long history of rejecting technology that looked impressive in presentations but created friction inside actual hospitals, and investors increasingly understand that reality. Cadence appears to be positioning itself on the opposite side of that equation.

Why This Matters

The AI conversation is evolving. For much of the past few years, healthcare AI discussions centered around possibility. Large language models could summarize notes, algorithms could identify risks, and automation could reduce administrative burden. The challenge was always operational reality because healthcare is not social media, advertising, or e-commerce. When technology makes a mistake in healthcare, people notice in ways that are considerably less forgiving.

That is why the metrics Cadence cites are drawing attention. The company reports supporting more than 100,000 active patients while working with over 20 health systems nationwide. Cadence also says its model delivers more than $3 in Medicare savings for every $1 spent and saves Medicare approximately $2.7M every week, according to company-reported outcomes data. Those figures matter because they move the conversation from capability to economics. Healthcare executives are under growing pressure to demonstrate measurable outcomes, and investors are increasingly demanding the same. The market is shifting from whether AI can do something to whether AI creates measurable value, and that distinction is where companies begin separating themselves from the broader AI crowd.

Market Context

Chronic disease remains one of the largest cost drivers in American healthcare. According to the Centers for Medicare & Medicaid Services, healthcare spending continues to be heavily influenced by chronic conditions, particularly among older adults. More than 56M older adults in the United States live with chronic disease and require ongoing care management. Historically, healthcare systems have struggled with that reality because clinicians cannot continuously monitor every patient and patients frequently experience issues long before scheduled follow-up visits.

Small problems become larger problems, and larger problems become emergency department visits, hospital admissions, and higher costs. Cadence's Clinical Intelligence platform, available through Cadence, serves as the operational layer connecting remote monitoring, clinical intervention, and health-system workflows. The company says the platform continuously monitors patient data, identifies risk factors, supports medication adjustments, and helps coordinate interventions before conditions escalate. Cadence also announced new affiliations with Duke Health and Texas Health Resources as it expands across major U.S. health systems. This approach aligns with the broader movement toward value-based care, where providers are rewarded for improving outcomes and lowering costs rather than simply increasing service volume.

Competitive Landscape

Cadence operates within the growing categories of clinical AI, remote patient monitoring, virtual care, and healthcare infrastructure software. What differentiates successful companies in these categories is rarely technology alone. Healthcare technology succeeds when clinicians, administrators, patients, and payers all find value in the same system. That alignment is notoriously difficult, which is why many promising healthcare technologies struggle to achieve widespread adoption.

Cadence reports outcomes including a 230% increase in heart failure patients receiving guideline-directed medical therapy, a 70% relative increase in blood pressure control, a 27% reduction in hospital admissions, and a $1,302 annual reduction in total cost of care per patient. Whether those results continue to scale remains one of the most important questions for the broader healthcare AI market. The company's growth suggests investors believe Cadence has moved beyond isolated pilots and into operational deployment at meaningful scale.

What This Signals

This funding round says something larger about healthcare AI. The market is becoming less interested in AI as a feature and more interested in AI as infrastructure. Investors are increasingly rewarding companies that embed themselves directly into operational workflows rather than existing as standalone tools. The companies attracting the most attention are increasingly the ones solving operational problems rather than creating new dashboards.

Cadence's leadership team reflects that focus. Alongside Chris Altchek, Founder and CEO, and Kareem Zaki, Co-Founder, the company recently expanded its executive bench with Casey Bailey, Chief People Officer (CPO), and Chris Holmes, Chief Financial Officer (CFO). The Series C round also adds Will Reed, Partner at Spark Capital, to the board. These are not signals of a company optimizing for headlines. They are signals of a company preparing for scale.

The Bigger Industry Shift

The most important AI companies in healthcare may not be the ones generating the loudest headlines. They may be the companies quietly inserting themselves into the daily operations of hospitals, health systems, and care teams because that is where healthcare economics are won or lost. The next decade of healthcare AI will likely be defined less by what algorithms can theoretically accomplish and more by whether they can consistently improve outcomes, reduce costs, and fit into the messy reality of clinical care.

Cadence's $100M Series C follows earlier funding rounds backed by investors including General Catalyst, Thrive Capital, and Coatue, signaling continued conviction in the company's approach to chronic disease management. The broader question is no longer whether AI will participate in healthcare delivery. The question is which companies become essential enough that healthcare systems eventually cannot imagine operating without them.